{
    "organizations": [],
    "uuid": "c101e487fe6eeaba39f1ee8d730943964832b70b",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-eiger-announces-expanded-license-a/brief-eiger-announces-expanded-license-agreement-with-merck-for-lonafarnib-idUSFWN1SN0GD",
    "ord_in_thread": 0,
    "title": "BRIEF-Eiger Announces Expanded License Agreement With Merck For Lonafarnib",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 16 (Reuters) - Eiger BioPharmaceuticals Inc:\n* EIGER ANNOUNCES EXPANDED LICENSE AGREEMENT WITH MERCK FOR INVESTIGATIONAL CANDIDATE LONAFARNIB AND COLLABORATION WITH THE PROGERIA RESEARCH FOUNDATION (PRF) Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-16T20:16:00.000+03:00",
    "crawled": "2018-05-17T14:24:15.041+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "eiger",
        "biopharmaceuticals",
        "inc",
        "eiger",
        "announces",
        "expanded",
        "license",
        "agreement",
        "merck",
        "investigational",
        "candidate",
        "lonafarnib",
        "collaboration",
        "progeria",
        "research",
        "foundation",
        "prf",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}